Therefore, patients with stage II–III CRC harboring KRAS G12A, representing a small but high-risk subset, may benefit from more potent adjuvant chemotherapy regimens, combined with more intensive postoperative surveillance. The gene discussed is KRAS; the disease is colorectal carcinoma.